Cryo-Cell International, Inc. (CCEL)
NYSEAMERICAN: CCEL · Real-Time Price · USD
3.630
-0.350 (-8.79%)
Dec 2, 2025, 3:09 PM EST - Market open
Cryo-Cell International Revenue
Cryo-Cell International had revenue of $7.83M in the quarter ending August 31, 2025, a decrease of -2.99%. This brings the company's revenue in the last twelve months to $31.75M, down -0.29% year-over-year. In the fiscal year ending November 30, 2024, Cryo-Cell International had annual revenue of $31.99M with 2.05% growth.
Revenue (ttm)
$31.75M
Revenue Growth
-0.29%
P/S Ratio
1.01
Revenue / Employee
$369,157
Employees
86
Market Cap
29.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Nov 30, 2024 | 31.99M | 642.41K | 2.05% |
| Nov 30, 2023 | 31.34M | 1.01M | 3.32% |
| Nov 30, 2022 | 30.34M | 1.45M | 5.03% |
| Nov 30, 2021 | 28.88M | -2.26M | -7.26% |
| Nov 30, 2020 | 31.15M | -668.98K | -2.10% |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CCEL News
- 6 weeks ago - Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2025 Financial Results - Business Wire
- 3 months ago - Cryo-Cell International, Inc. Provides Dividend Update - Business Wire
- 4 months ago - Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results - Business Wire
- 7 months ago - Cord Blood Banking Leader Cryo-Cell Announces Cash Dividend - Business Wire
- 9 months ago - Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2024 - Business Wire
- 10 months ago - Cord Blood Banking Leader Cryo-Cell Announces Regular Quarterly Cash Dividend and Pause of Strategic Initiatives - Business Wire
- 1 year ago - Cord Blood Banking Leader Cryo-Cell Declares Initiation of Regular Quarterly Cash Dividend - Business Wire
- 1 year ago - Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2024 Financial Results - Business Wire